BOSTON, March 31, 2026 (GLOBE NEWSWIRE) — Block & Leviton broadcasts {that a} securities fraud lawsuit has been filed towards Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) and sure of its executives. Traders who’ve misplaced cash of their Aldeyra Therapeutics funding ought to contact the agency to be taught extra about how they may recuperate these losses. For extra particulars, go to https://blockleviton.com/instances/aldx.
What is that this all about?
Shares of Aldeyra Therapeutics fell over 65% in buying and selling on March 17, 2026, after the corporate disclosed that it obtained a Full Response Letter from the U.S. Meals and Drug Administration for reproxalap for dry eye illness. Aldeyra acknowledged that the applying “has failed to demonstrate efficacy in adequate and well controlled studies in the treatment of signs and symptoms of dry eye disease” and that “the totality of evidence from the completed clinical trials does not support the effectiveness of the product.” Aldeyra beforehand disclosed on April 3, 2025 that the FDA acknowledged the reproxalap NDA “failed to demonstrate efficacy in adequate and well controlled studies in treating ocular symptoms associated with dry eyes” and that “at least one additional adequate and well controlled study to demonstrate a positive effect on the treatment of ocular symptoms of dry eye” ought to be carried out.
Who’s eligible?
Anybody who bought Aldeyra Therapeutics widespread inventory between November 3, 2023, and March 16, 2026, and has seen their shares fall could also be eligible, whether or not or not they’ve offered their funding. Traders ought to contact Block & Leviton to be taught extra.
More Read
What do you have to do subsequent?
Whistleblower?
Why do you have to contact Block & Leviton?
More Read
This discover could represent lawyer promoting.
